drugset / Trial / NCT02524054
Aerosol Inhalation Treatment for Dyspnea - Patients
Phase 1/2
Completed
24 enrolled
Beth Israel Deaconess Medical Center
National Institute of Nursing Research (NINR) · collab
RandomizedCrossoverDouble-blindSupportive care
Summary
The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.
Timeline
- Start
- 2014-11-01
- Primary completion
- 2016-11-30
- Completion
- 2017-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furosemide | Other / unclassified | 40 mg | Inhaled |
| Subject | Furosemide | Other / unclassified | 80 mg | Inhaled |
Indications
No indication recorded.